Merck (MRK) stock is drawing fresh attention after a cluster of June 2026 pipeline milestones, including new FDA approvals for KEYTRUDA plus WELIREG and CAPVAXIVE, and Phase 3 success for ulcerative colitis drug tulisokibart.

Despite these approvals and positive trial updates, Merck’s recent 30-day share price return is down 5.66%, while the year-to-date share price return is 8.48% and the 1-year total shareholder return is 48.88%. This suggests that longer term momentum remains stronger than the short term reaction.

If Merck’s pipeline activity has your attention, it can be useful to scan other potential healthcare growth stories through the Simply Wall St screener for 38 healthcare AI stocks

With Merck trading at US$115.48, a 12.7% discount to the average analyst price target and a 46% gap to one intrinsic value estimate, the key question is whether this signals a genuine opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 11% Undervalued

Merck is trading at $115.48 against a widely followed fair value estimate of $129.74, which puts the current price below that narrative benchmark.

With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth. The ongoing strong launches of key new products, such as WINREVAIR and CAPVAXIVE, are positively impacting revenues and are expected to support further growth in the coming years.

Want to understand why this fair value sits above today’s share price? The narrative leans heavily on higher margins, faster earnings growth and a richer future multiple. Curious which specific assumptions underpin that outlook and how they fit together in the model?

Result: Fair Value of $129.74 (UNDERVALUED)

However, Merck’s story is not risk free. KEYTRUDA’s eventual loss of exclusivity and GARDASIL softness in China are both capable of challenging that undervalued narrative.

Another View: What Merck’s P/E Says

While one narrative pegs Merck at an 11% discount to a fair value of $129.74, the current P/E of 31.9x stands above both the US Pharmaceuticals industry at 14.9x and peers at 25x, and only slightly below a fair ratio of 33.5x. This points to less obvious valuation slack and raises a question: how comfortable are you paying a premium multiple when a fair ratio suggests the market could already be close to fully pricing it?

Next Steps

If the mix of optimism and concern around Merck feels finely balanced, consider reviewing the data promptly to evaluate the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Merck?

If Merck has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas that match different investing goals and risk levels.

• Spot potential high-growth opportunities early by scanning screener containing 19 high quality undiscovered gems that pair solid business fundamentals with limited current attention.
• Build a steadier core by reviewing 66 resilient stocks with low risk scores designed for investors who want resilience when markets turn choppy.
• Strengthen your income stream by checking 7 dividend fortresses that combine 5%+ yields with an emphasis on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.